Literature DB >> 32504292

GMP-Compliant Production of Human Placenta-Derived Mesenchymal Stem Cells.

Hamid Reza Aghayan1, Moloud Payab2, Fereshteh Mohamadi-Jahani3, Seyed Sajjad Aghayan4, Bagher Larijani5, Babak Arjmand6,7.   

Abstract

Mesenchymal stem cells are one of the most attractive sources for stem cell research and therapy. Their safety and efficacy have been demonstrated in many clinical trials. Because of their low immunogenicity and immunomodulatory properties, allogenic MSCs have been transplanted in different clinical studies. MSCs could be in different adult- and fetal-derived tissues including pregnancy products. Placenta-derived mesenchymal stem cells (PLMSCs) that can be harvested without using any invasive procedures from a discarding tissue are one of the important types of mesenchymal stem cells for therapeutic applications. Stem cell manufacturing for therapeutic applications should be in compliance with the basic principles of good manufacturing practice (GMP). Herein, the current chapter is to describe GMP-compliant production of human PLMSCs, which are suitable for clinical applications.

Entities:  

Keywords:  Cell culture; Cell therapy; Clinical application; GMP; Mesenchymal stem cells; Placenta

Year:  2021        PMID: 32504292     DOI: 10.1007/7651_2020_282

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

1.  Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art.

Authors:  Arianna Malgieri; Eugenia Kantzari; Maria Patrizia Patrizi; Stefano Gambardella
Journal:  Int J Clin Exp Med       Date:  2010-09-07

2.  A simple and cost-effective method for isolation and expansion of human fetal pancreas derived mesenchymal stem cells.

Authors:  Bagher Larijani; Babak Arjmand; Naser Ahmadbeigi; Khadijeh Falahzadeh; Masoud Soleimani; Forough Azam Sayahpour; Hamid Reza Aghayan
Journal:  Arch Iran Med       Date:  2015-11       Impact factor: 1.354

3.  Cell therapy: cGMP facilities and manufacturing.

Authors:  Raffaella Giancola; Tiziana Bonfini; Antonio Iacone
Journal:  Muscles Ligaments Tendons J       Date:  2012-10-16

4.  Clinical Grade Human Adipose Tissue-Derived Mesenchymal Stem Cell Banking.

Authors:  Bagher Larijani; Hamidreza Aghayan; Parisa Goodarzi; Fereshteh Mohamadi-Jahani; Abbas Norouzi-Javidan; Ahmad Reza Dehpour; Khadijeh Fallahzadeh; Forough Azam Sayahpour; Kazem Bidaki; Babak Arjmand
Journal:  Acta Med Iran       Date:  2015

Review 5.  Stem cell-based approach for the treatment of Parkinson's disease.

Authors:  Parisa Goodarzi; Hamid Reza Aghayan; Bagher Larijani; Masoud Soleimani; Ahmad-Reza Dehpour; Mehrnaz Sahebjam; Firoozeh Ghaderi; Babak Arjmand
Journal:  Med J Islam Repub Iran       Date:  2015-01-28

6.  Epigenotoxic Effect of Dimethyl Sulfoxide on Buffalo Somatic Cells and Buffalo-Bovine Interspecies Somatic Cell Nuclear Transfer Embryos.

Authors:  Husamaldeen Alsalim; Farnoosh Jafarpour; Faezeh Ghazvini Zadegan; Mohammad Hossein Nasr-Esfahani; Amir Niasari-Naslaji
Journal:  Cell J       Date:  2018-08-01       Impact factor: 2.479

  6 in total
  3 in total

1.  Placenta derived Mesenchymal Stem Cells transplantation in Type 1 diabetes: preliminary report of phase 1 clinical trial.

Authors:  Sedighegh Madani; Aria Setudeh; Hamid Reza Aghayan; Sepideh Alavi-Moghadam; Mahtab Rouhifard; Negar Rezaei; Parastoo Rostami; Reihaneh Mohsenipour; Davoud Amirkashani; Fatemeh Bandarian; Babak Arjmand; Bagher Larijani
Journal:  J Diabetes Metab Disord       Date:  2021-07-09

Review 2.  Advancement of Organoid Technology in Regenerative Medicine.

Authors:  Babak Arjmand; Zahra Rabbani; Faezeh Soveyzi; Akram Tayanloo-Beik; Mostafa Rezaei-Tavirani; Mahmood Biglar; Hossein Adibi; Bagher Larijani
Journal:  Regen Eng Transl Med       Date:  2022-08-08

3.  Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.

Authors:  Hamid Reza Aghayan; Fatemeh Salimian; Atefeh Abedini; Samrand Fattah Ghazi; Masud Yunesian; Sepideh Alavi-Moghadam; Jalil Makarem; Keivan Majidzadeh-A; Ali Hatamkhani; Maryam Moghri; Abbas Danesh; Mohammad Reza Haddad-Marandi; Hassan Sanati; Fereshteh Abbasvandi; Babak Arjmand; Pourya Azimi; Ardeshir Ghavamzadeh; Ramin Sarrami-Forooshani
Journal:  Stem Cell Res Ther       Date:  2022-07-28       Impact factor: 8.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.